We are Homology

Our mission is focused on curing disease and transforming patients’ lives

Paul Alloway, Ph.D., J.D.

President and Chief Operating Officer

“Working at Homology to develop transformative life-changing therapies for patients with rare diseases with significant unmet need is a privilege. We know that every second counts for these patients, so we aim to work quickly and efficiently – but always with integrity and a focus on compliance, quality and safety.”

photo for Paul Alloway, Ph.D., J.D.

Paul Alloway, Ph.D., J.D., serves as the President and Chief Operating Officer of Homology Medicines and previously served as Chief Legal Officer.  Dr. Alloway brings more than 20 years of relevant legal and leadership experience acquired from working in the biotechnology industry, private equity and private practice. Prior to joining Homology, Dr. Alloway was Vice President, Head of Legal and Corporate Secretary at Foghorn Therapeutics, where he had responsibility for all legal matters, including intellectual property, compliance, transactions, financings and corporate governance. Before joining Foghorn, Dr. Alloway was Vice President & Senior Counsel at DRI Capital, a Canadian private-equity firm that specializes in pharmaceutical healthcare royalty investments, where he oversaw a team that was responsible for conducting patent, regulatory and legal due diligence, drafting and negotiating agreements, conducting financings and securitizations and overseeing litigation and governance matters. Earlier in his career, Dr. Alloway spent nine years as a patent attorney at Alexion and Genzyme, where he supervised and managed a team responsible for IP operations and provided broad-based legal and IP-related support for numerous commercial, clinical and preclinical products. Dr. Alloway began his career at an IP boutique firm, where he prepared and prosecuted patent applications in a wide range of technologies, including biotechnology, pharmaceuticals and medical devices. Dr. Alloway obtained his B.Sc. in Biology from the University of Toronto, his Ph.D. in Molecular and Cellular Biology from Dartmouth College and his J.D. from Suffolk University Law School.